Opinion
Video
EGFR-Mutated NSCLC Disease Risk Stratification
Panelists discuss how disease-related factors like central nervous system (CNS) involvement or specific metastatic sites can guide treatment selection, favoring agents with CNS penetration or targeted efficacy. Mutational factors, such as TP53 comutations, may impact therapy response. Patient-related aspects, including age and comorbidities, influence tolerability and regimen choice.
Video content above is prompted by the following:
- In your expertise, which disease-related factors, such as CNS involvement or site of metastases, might suggest a preference for one treatment over the others?
- What about mutational factors—for example, a TP53 comutation? Additionally, how do patient-related factors such as age and comorbidities influence your choice?
Latest CME
View All
Video
Addressing Unmet Needs in HER2+ Metastatic BTC
Apr 18th 2025 - Apr 19th 2026
online-activity
Video
Community Oncology Connections™: Case Discussions in TNBC…Navigating the Latest Advances and Impact of Disparities in Care | North Carolina
Apr 17th 2025 - May 23rd 2025
online-activity
Video
Community Oncology Connections™: Community Oncologists’ Role in Selecting Optimal Oral SERD Treatment for HR+/HER2– Breast Cancer | Minnesota
Apr 17th 2025 - May 23rd 2025
online-activity
Related Content
.png?fit=crop&auto=format)
.jpg?fit=crop&auto=format)
